The Report China Diagnostic Reagent Industry Report, 2013-2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz

Albany, NY -- (SBWire) -- 06/08/2015 --With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.

Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.

View Full Report at http://www.marketresearchreports.biz/analysis/213590

Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.

Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.

Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/213590

In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.

Table of Content

1 Overview of Diagnostic Reagent Industry
1.1 Definition
1.2 Classification
1.3 Industry Chain

2 Status Quo of China Diagnostic Reagent Industry
2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competition Pattern
2.5 Market Segments
2.5.1 Biochemical Diagnostic Reagents
2.5.2 Immunodiagnostic Reagents
2.5.3 Molecular Diagnostic Reagents
2.5.4 Comprehensive In Vitro Diagnostic Reagents

3 Development Environments and Trends of China Diagnostic Reagent Industry
3.1 Positive Factors
3.1.1 Macroeconomy
3.1.2 Medical Care
3.1.3 Policies
3.2 Trends

About MarketResearchReports.biz
Marketresearchreports.biz (http://www.marketresearchreports.biz/) is the most comprehensive collection of market research reports, supporting clients' market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.

Read our latest articles at http://www.marketresearchreports.biz/articles

Contact:
Toll Free: 866-997-4948
(USA-CANADA)

Tel: 518-618-1030
E: sales@marketresearchreports.biz